Boston Scientific’s new DBS system obtains CE mark

6 June 2017 (Last Updated June 6th, 2017 18:30)

US-based Boston Scientific has obtained CE marking for its deep brain stimulation (DBS) system called Vercise Gevia.

US-based Boston Scientific has obtained CE marking for its deep brain stimulation (DBS) system called Vercise Gevia.

Vercise Gevia is a rechargeable, magnetic resonance (MR) conditional device developed to treat movement disorder symptoms associated with Parkinson's disease, dystonia and essential tremor.

The device employs the Vercise Neural Navigator 2 programming software with STIMVIEW technology to enable visualisation of the stimulation field during configuration of DBS stimulation programmes for patients.

Boston Scientific Neuromodulation senior vice-president and president Maulik Nanavaty said: "Five years ago, Boston Scientific was the first to bring an eight contact rechargeable platform offering 25 years of longevity, quickly followed by the introduction of the first directional lead powered by a small primary cell device."

"With a battery life of 25 years, the new system is said to address the patient and physician needs."

The new system expands the firm’s Vercise Directional portfolio that comprises the Vercise Primary Cell (PC) and Vercise Gevia platforms with Vercise Cartesia Directional Lead, designed to control the size, shape and direction of stimulation using multiple independent current control technology (MICC).

During DBS therapy, a device uses electrical signals to stimulate certain areas of the brain, and precise stimulation to the neural target is considered important to avoid unwanted side effects and for optimal DBS outcomes.

With a battery life of 25 years, the new system is said to address the patient and physician needs, as well as offer the advantage of directional stimulation within a rechargeable system.